Ascendis Pharma announced 5-year Phase 2 trial results for TransCon PTH, showing sustained efficacy and safety in adults with hypoparathyroidism. The treatment replicated natural parathyroid hormone effects, improving kidney function, calcium levels, bone density, and quality of life while reducing dependence on conventional vitamin D and calcium therapy. With 95% of patients completing the trial and no new safety concerns, TransCon PTH shows promise as a new standard of care for this chronic condition. The company plans to continue monitoring and developing this therapy.
Ascendis Pharma reported positive five-year results from its Phase 2 PaTH Forward trial of TransCon PTH (palopegteriparatide) for adult hypoparathyroidism. The therapy maintained stable calcium levels, kidney and bone health, and quality of life, all...
The Touchstone Mid Cap Growth Fund (Class A Shares, Load Waived) outperformed its benchmark, the Russell Midcap Growth Index, for the quarter ended March 31, 2026. Key contributors to this strong performance included Vertiv Holdings, Ascendis Pharma,...
Ascend Learning's ATI Engage® Series won the Digital Learning Innovation Award at the 2026 EdTech Breakthrough Awards for its advanced digital platform that enhances nursing education. The platform uses AI to personalize learning, offering interactiv...
Ascendis Pharma announced it will share new clinical trial data on treatments for rare endocrine diseases including hypoparathyroidism, achondroplasia, and pediatric growth hormone deficiency at the ENDO 2026 conference in Chicago. The presentations ...
